|
Dr Mark Payton
Chief Executive Officer & Chief Scientific Officer
Dr Mike
Perkins
Director of Development & Chief Medical Officer
Richard Onyett
Commercial Director
Dr Mick
Hunter
Director of Discovery & Development Projects
Dr Roy Pettipher
Director of Pharmacology
Paul Foster
Finance Director
|
|
Dr Roy Pettipher
Director of Pharmacology
Dr Roy Pettipher joined Oxagen in April
1999 and was responsible for the initiation of the GPCR programme.
Prior to joining Oxagen, Roy gained 13 years experience in
anti-inflammatory drug discovery during his time at Pfizer
in the US and, previous to that, at Wellcome in the UK.
In the past, Roy has been involved in the initiation and
management of a number of drug discovery programmes that
have yielded clinical candidates and has published extensively
in the field of inflammation biology. His expertise in
inflammation biology has proved valuable in the selection
and prosecution
of CRTH2 as a target for allergic disorders.
|
